Year All2024202320222021202020192018201720162015201420132012201120102007 10.15.10 Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat--Patent issuance extends entinostat exclusivity to 2029-- Read More 09.28.10 Syndax Pharmaceuticals to Present at BIO Investor Forum Read More 09.22.10 Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum Read More 09.16.10 Syndax Pharmaceuticals to Present at UBS 2010 Global Life Sciences Conference Read More 09.09.10 Syndax Pharmaceuticals to Present at R.W. Baird 2010 Healthcare Conference and BioPharm America 2010 Read More 08.11.10 Syndax Pharmaceuticals raises $6 Million in Securities Offering - Funding to Support Completion of Randomized Phase 2 Breast Cancer Study in First Half 2011- Read More 06.04.10 Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer - Data to be presented at the American Society of Clinical Oncology annual meeting – Read More 05.24.10 Syndax Pharmaceuticals Inc. to Present Entinostat Data Showing Benefit in Combination in Advanced Breast Cancer at ASCO Read More 06.06.07 FierceBiotech Names Syndax Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2007 Syndax Pharmaceuticals is "Fierce," on Leading Edge of Biotech Read More 04.13.07 Syndax Pharmaceuticals Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275 Clinical oncology compound already tested in over 200 patients Read More 04.03.07 Syndax Pharmaceuticals Inc. closes $40 Million Series A Financing Funds to support pipeline development Read More
10.15.10 Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat--Patent issuance extends entinostat exclusivity to 2029-- Read More
09.09.10 Syndax Pharmaceuticals to Present at R.W. Baird 2010 Healthcare Conference and BioPharm America 2010 Read More
08.11.10 Syndax Pharmaceuticals raises $6 Million in Securities Offering - Funding to Support Completion of Randomized Phase 2 Breast Cancer Study in First Half 2011- Read More
06.04.10 Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer - Data to be presented at the American Society of Clinical Oncology annual meeting – Read More
05.24.10 Syndax Pharmaceuticals Inc. to Present Entinostat Data Showing Benefit in Combination in Advanced Breast Cancer at ASCO Read More
06.06.07 FierceBiotech Names Syndax Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2007 Syndax Pharmaceuticals is "Fierce," on Leading Edge of Biotech Read More
04.13.07 Syndax Pharmaceuticals Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275 Clinical oncology compound already tested in over 200 patients Read More
04.03.07 Syndax Pharmaceuticals Inc. closes $40 Million Series A Financing Funds to support pipeline development Read More